Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Apr 26, 2021Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in all infants.1-5
-
Oct 21, 2020* $1 million in research funding to support PD GENEration, a first-of-its-kind national study offering free genetic testing and counseling for people with Parkinson's disease (PD)
-
Oct 13, 2020Data in children aged 6-11 further suggest Dupixent has potential to be best-in-class treatment option
-
Sep 14, 2020* Designation based on positive results from Part A of pivotal Phase 3 trial
-
Sep 9, 2020- New data on investigational brain-penetrant BTK inhibitor tolebrutinib (SAR442168) further support its potential in modulating disabling inflammatory processes within the central nervous system
-
Aug 17, 2020* Further strengthens core R&D areas of autoimmune and allergic diseases
-
Jul 31, 2020- Promising vaccine candidate selected by U.S. government’s Operation Warp Speed
-
Jul 30, 2020- Nirsevimab reduced respiratory syncytial virus (RSV) lower respiratory tract infections by 70 percent and related hospitalizations by 78 percent1
-
Jul 14, 2020* New alliance will use insights from translational and clinical studies to better identify targets, combinations and potential new indications for current medicines